Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wilfactin for Prevention of Hemorrhage in CF-LVAD
NCT02488525Phase 3Terminated
- Sponsor
- CHU de Lille
- Start
- Jan 2016
- Primary completion
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of von Willebrand factor human in acquired von Willebrand syndrome (AvWS), sponsored by CHU de Lille. Started Jan 2016; status: terminated.
02
Drugs
von Willebrand factor human
03
Conditions
acquired von Willebrand syndrome (AvWS)
Beyond the preview
Go deeper on NCT02488525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02488525.